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ABSTRACT 
· The effect of the Jong acting dihydropyridine calcium channel antagonist, amlodipine, on 
the exercise performance of hypertensive patients is not known. The aim of this study 
was to determine the effects of amlodipine on maximal (MAX), prolonged submaximal 
(PSX) and on skeletal muscle function (SMF) in patients with mild hypertension. In a 
double-blind randomised crossover trial, ten physically active hypertensive patients 
performed i) graded exercise to exhaustion for determination of maximal oxygen 
consumption (V02max), peak heart rate (HR) and systolic blood pressure (SBPt ii) PSX at 
75% V02max to determine, cardiorespiratory responses, cardiac output (Q), blood lactate 
[La], free fatty acid [FFA], glucose [G] concentrations and ratings of perceived exertion 
(RPE), and iii) tests of isometric SMF including maximal voluntary contraction (MVC) 
and time to fatigue (TTF) during repetitve isometric MVC's. Tests were performed 
following two week ingestion of amlodipine (5 mg daily) or placebo seperated by a two 
week washout period. Resting SBP was decreased following ingestion of amlodipine 
( 142 ± 13 vs l33 ± 12 mmHg; vs placebo: [mean± SOL P<0.05). However, V02max (31 
± 5 vs 33 ± 5 ml02.kg.min-
1
; amlodipine vs placebo), peak heart rate ( 167 ± 12 vs 165 ± 
l6b.min·
1;amlodipinevsplacebo)andpeakSBP(l8l ±21 vs 170± 16mmHg; 
amlodipine vs placebo) were not reduced following ingestion of amlodipine. 
Submaximal cycling time. VO;., Q, BP, HR, ventilation, RPE, [Ff A], [La·] and [G] during 
PSX were unaltered following ingestion of amlodipine. Similarly ingestion of amlodipine 
did not alter tests of isometric SMF. These data suggest that: i) ingestion of amlodipine 
lowers resting SBP but does not alter the normal haemodynamic response during 
4 
exercise; ii) MAX, PSX exercise performance and SMF are unaltered following ingestion 
of amlodipine in athletic hypertensive patients. These findings suggest that the regulatory 
mechanisms which maintain haemodynamic homeostasis during maximal and 





A lack of regular aerobic exercise is currently listed as one of the major risk factors for 
cardiovascular mortality. The most recent report of the joint national comittee on 
detection , evaluation and treatment of high bloood pressure (JNC V) lists regular 
physical activity as one of the lifestyle modifications to be instituted in the primary 
prevention and management of hypertension. With the Calcium antagonists and 
angiotensin converting enzyme (ACE) inhibitors now joining the diuretics and beta-
blockers as acceptable first line therapy in the treatment of hypertension, it is important 
that the hypertensive individual is managed according to his or her needs and experiences 
(50, 63). 
Clearly, the physically active hypertensive is such an individual that needs the 
appropriate 'tailoring' of therapy. Whilst effective in lowering the maximum blood 
pressure during exercise, much current data on the effect of beta blockade appears to 
indicate a reduction in exercise performance and an alteration in the physiological 
response. Beta blockade can effect the biochemical and physiological response to 
exercise at many levels. Both cardioselective and non selective beta blockers impair 
exercise performance, however it is likely that submaximal performance is impaired to a 
greater degree by non selective beta blockade ( 18, 29, 55, 62, 65, 68.; ?O). Briefly, the 
proposed mechanisms whereby beta blockade limits exercise performance include: 
i) Central Haemodynamics. 
6 
Heart rate and systolic blood pressure at rest and during exercise are decreased by beta 
blockers (7, 13, 17). Much of the current data indicates that beta blockade decreases 
cardiac output at rest and during both maximal and submaximal exercise by between 5 -
15% (7, 9, 23). The reduction in exercise performance and increased fatigue has 
historically been attributed to these central haemodynamic changes. However, further 
analysis would question this hypothesis. First, a relative reduction in cardiac output 
during exercise is not a consistent finding ( 48). Beta blockers with intrinsic 
sympathomimetic activity limit the reduction in cardiac output, however, both maximal 
and submaximal exercise performance are impaired to the same degree as that with other 
beta blockers ( 19, 3 8). Second, various beta blockers alter maximal exercise performance 
even though they have no significant effect on cardiac output or total peripheral 
resistance measured during submaximal exercise ( 48). Therefore, it is unlikely that 
central factors alone could impair exercise performance. 
ii) Peripheral Haemodynamics. 
The majority of studies on peripheral blood flow in exercising limbs with beta blockade 
demonstrate a decrease in blood flow to exercising muscle (22, 37, 45). However, the 
arteriovenous oxygen content difference is increased such that submaximal oxygen 
consumption (V02) is unchanged during submaximal exercise (22). The reduction in 
skeletal muscle blood flow is likely to be worse with the non selective beta blockers 
where unopposed alpha mediated vasoconstriction would occur under catecholamine 
stimulation during exercise (22, 45). Therefore, it is likely that blood flow to working 
muscle is affected by beta blockade but oxygen delivery is possibly unaltered (22). 
However, it is possible that diminished blood flow during exercise could allow for the 
accumulation of cellular metabolites, such as lactate and potassium, and thus impairing 
performance. 
iii) Lipolysis. 
Beta blockade inhibits adipose tissue lipolysis and therefore attenuates the increase in 
plasma free fatty acids that would normally occur during prolonged exercise and thereby 
possibly altering skeletal muscle substrate metabolism (35, 55, 65, 66). 
iv) Glycolysis. 
During submaximal exercise under beta blockade, plasma lactate concentrations tend to 
be higher with a lower relative oxygen consumption (V02) when compared to placebo 
(70). The relative respiratory exchange ratios are higher after the ingestion of beta 
blockers suggesting a greater dependance on carbohydrate as an energy substrate. 
Therefore if there were a reduction in hepatic glycogenolysis due to beta 2 receptor 
blockade, this might result in a decrease in plasma glucose concentration and thereby 
impair exercise performance (55). However, it would appear that low plasma glucose 
concentrations are found only in fasting subjects undergoing submaximal exercise and 
normally fed subjects undergoing high intensity exercise (65). Assuming that athletes are 
generally well fed, those subjects participating in high intensity exercise under beta 
blockade may be at risk of developing hypoglycaemia, however, the evidence for 
impaired glycogenolysis in skeletal muscle is indirect and glycogenolysis is probably 
maintained by mechanisms independant of the beta receptor (55). 
v) Hormonal effects of beta blockade. 
The increase in plasma adrenaline concentration is augmented by beta blockade during 
exercise whereas the increase in plasma noradrenaline concentration during submaximal 
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exercise is unchanged (11, 24, 46). Kindermann et al ( 1982) reported significant 
increases in plasma concentrations of noradrenaline, adrenaline, growth hormone, 
glucagon, and cortisol during submaximal exercise following Bl - selective blockade 
compared to placebo. 
Serum insulin and oestradiol concentrations are unaffected whereas serum testosterone 
concentration is decreased by Bl - selective blockade during submaximal exercise (35). 
Growth hormone concentrations during exercise are increased by selective and non 
selective B blockade (35). 
It is possible that the increase in the concentration of adrenaline, growth hormone, 
glucagon and cortisol allows for the mobilisation of alternative fuel sources, such as 
carbohydrates, as free fatty acid metabolism is impaired by beta blockade (35, 55). 
vi) Ventilation. 
It is possible that the respiratory response to exercise is affected by beta blockade. Both 
cardioselective and non selective beta blockers would appear to attenuate the normal 
increase in tidal volume with increasing work rate, the latter to a greater degree than the 
former, highlighting the importance of beta 2 mediated bronchodilation (33). However, 
minute ventilation and carbon dioxide production (VC02) are unaltered due to an 
increase in breathing frequency (33). Therefore it is possible that the maintenance of 
minute ventilation, at the cost of an increase in breathing frequency, might result in an 




During prolonged exercise beta blockade may interfere with the regulatory mechanisms 
involved in controlling body temperature thereby affecting performance. Increased sweat 
losses and the elevation of pulmonary artery temperature has been documented in 
exercising subjects under non selective beta blockade (27). 
In summary, the commonly prescribed beta blockers undoubtedly affect exercise 
performance. When both exercise programmes and pharmacological agents are 
prescribed to hypertensive patients, who are not limited by ischaemic heart disease, it is 
essential that an agent which does not impair the ability to exercise adequately, is 
selected. 
As a result there is a need to find more appropriate agents for the use in physically active 
individuals i.e. ones that reduce peripheral resistance whilst allowing a normal 
physiological and metabolic response to exercise. The use of either angiotensin 
converting enzyme (ACE) inhibitors or calcium channel antagonists would appear to be 
more appropriate. However, both groups of anti-hypertensives have been reported to 
impair exercise performance ( 17, 26, 67). Acute dosing with ACE inhibitors has shown a 
decrease in maximal and prolonged submaximal performance, as well as altering 
substrate metabolism during submaximal testing (17, 67). The recognition for the need of 
twenty four hour blood pressure control has enhanced the popularity of the long acting 
calcium channel antagonists such as amlodipine. The once daily dosing, smooth onset of 
action and limited vasodilatory side effects give these drugs an advantage over the shorter 
acting calcium antagonists such as nifedipine. However, few data are available on how 
these drugs affect performance and in particular their effect on prolonged submaximal 
performance in hypertensive individuals. The literature concerning calcium antagonists 
and exercise performance as well as the physical and metabolic response to exercise will 
be the focus of this review. 
Calcium Antagonists: 
The Calcium antagonists can be classified into two main groups, those of the verapamil 
type (phenylalkylamines and benzothiazepines) and those of the nifedipine type 
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( dihydropyridines ). Both groups lower blood pressure by acting on vascular smooth 
muscle and decreasing the total peripheral resistance, however, they also have a 
cardiodepressive effect which is seen predominantly in those drugs of the verapamil type 
whereas the nifedipine type or dihydropyridines have a predominant vasodilating action 
with little or no cardiodepressive effect (36). 
A review of the studies of calcium antagonists and their effects on the physiological 
response to exercise is presented below. The data are clarified if the two types of 
exercise, incremental graded (maximal) and prolonged submaximal exercise~ and the 
types of dosing~ acute versus chronic, are considered seperately. 
i) Maximal exercise performance 
Historically maximal exercise performance has been assessed by determining the 
V02max, maximal workload achieved (WL max) or time taken to exhaustion. Noakes et 
al ( 1990) question the predictive value of V02max as regards performance ( 51 ). Their 
findings suggest that peak treadmill running speed is a better predictor of performance 
than V02max· Therefore the interpretation of V02max data should be viewed with 
circumspection if correlations are made to performance. For completeness all the data 
traditionally measuring maximal exercise performance as V02max will be presented. 
l l 
The exercise studies can be grouped into those that used acute (single) doses of drug and 
those in which long term administration was used (table l). 
table 1. Performance during incremental graded exercise tests after the ingestion of various calcium 
antagonists.The frequency of the dose i.e either acute (stat) or long term administration is indicated. 
Study Drug Dose Exercise Type Performance 
Gordon et al 1986 Nifedipine 10 mg stat [GE 
,J., 
Diltiazem 60 mg stat IGE 7 
Veraparnil 80 mg stat [GE 7 
Derman et al 1992 Nifedipine 20 mg stat IGE 
,J., 
Raffestin et al 1985 Nifedipine 20 mg stat [GE 7 
Diltiazem 90 mg stat IGE 7 
Kindermann 1986 Nifedipine 40 mg daily IGE 7 
Diltiazem 180 mg daily IGE 7 
Petri 1986 Verapamil 120-360 mg daily IGE 7 
Yamakado et al 1983 Diltiazem 180mg daily IGE 7 
Luurila et al 1987 Diltiazem 216 mg daily IGE 7 
Symbols represent no change (7) or a decrease ('1,,) in performance. Abbreviations: lGE, 
incremental graded exercise. 
Gordon et al noted a significant reduction in V02max and performance time in 
normotensive subjects using cycle ergometry after a single dose of nifedipine 10 mg, 
however, after 60 mg diltiazem and 80 mg verapimil neither of these parameters were 
significantly altered (26 ). Raffest_in et al ( 1985) using a single dose of nifedipine 20 mg 
and diltiazem 90 mg did not detect a change in the V02max or maximum power output 
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after cycle ergometry in healthy individuals (58). Derman et al (1992) after a single dose 
of nifedipine 20 mg showed a significant decrease in time to exhaustion and peak work 
load achieved, however, the V02max was unchanged in normotensive subjects ( 17). 
The duration of drug administration in the 'long term' studies varied from three times 
daily for three days (Petri 1986) to once daily for one month (Luurila 1987). After the 
administration of nifedipine 40 mg daily and diltiazem 180 mg daily Kindermann failed 
to show a difference in the V02max or maximal treadmill speed (35). Petri ( 1986) after 
long term administration of verapimil 120 mg to 360 mg demonstrated no change in 
V02max (57). In hypertensive patients, Yamakado et al (1983) failed to show a change 
in performance on treadmill testing after long term administration of diltiazem 180 mg 
daily (71). Luurila et al (1987) demonstrated no change in peak work load achieved using 
diltiazem, mean dose 216 mg per day, versus placebo in hypertensive subjects after long 
term administration ( 44 ). 
A review of the data thus far is inconclusive in the findings that the calcium antagonists 
as a class attenuate maximal exercise performance. However, the majority of studies that 
used long term administration of such drugs did not show a reduction in performance 
data in both hypertensive and normotensive subjects. It would appear to be those studies 
that used acute dosing, and predominantly with nifedipine, that showed a decrease in one 
of the parameters traditionally used to measure performance. With invasive intra arterial 
blood pressure, cardiac output and peripheral resistance monitoring, Omvik and Lund 
Johansen ( 1993) detemined that the physiological changes that occur after the acute 
ingestion of a wide variety of anti hypertensives is different to that after long term 
ingestion. After acute dosing various counter regulatory processes are stimulated, 
however these responses may be attenuated over time with long term therapy (54). This 
acute alteration in physiology may contribute towards explaining why the findings of 
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acute dose studies frequently differ from the studies performed after long term ingestion, 
furthermore, applying the findings of the acute dose studies to hypertensive patients on 
long term therapy may be inappropriate. 
ii) Submaximal exercise performance : 
Relatively few studies have been undertaken looking at the effects of calcium antagonists 
on the ability to perform prolonged submaximal exercise (table 2). 
Table 2. Performance during prolonged submaximal exercise tests after the ingestion of various 
calcium antagonists. The frequency of the dose i.e either acute (stat) or long term administration is indicated. 
Study Drug Dose Exercise Type Performance 
Raffestin et al 1985 Nifedipine 20 mg stat PSME (60% V02max) 7 
Kindermann 1986 Nifedipine 20 mg b.d PSME (75% V02max) 7 
Diltiazem 60 mg t.d.s PSME (75% V02max> 7 
Selvey et al 1994 [sradipine 2.5 mg b.d PSME (75% VOzwax> ~ 
Symbols represent no change (7) or a decrease(~) in performance. Abbreviations: PSME, 
prolonged submaximal exercise. t.d .s, three times daily. b.d. twice daily. 
Raffestin et al used nifedipine 20 mg in subjects cycling at 60% of their V02max for 45 
minutes. All of these subjects completed both the placebo and nifedipine trial (58). He 
noted no difference in oxygen consumption. Kindermann et al studied the effects of 
nifedipine 20 mg twice daily and diltiazem 60 mg three times daily on prolonged 
exercise performed at 75%> of V02max for 50 minutes on a treadmill. In this study, all of 
the subjects completed the 50 minutes and there was no difference in the rating of 
perceived exertion when compared to placebo (36). These two trials are limited by the 
fact that the prolonged exercise was stopped at 45 minutes (Raffestin) and 50 minutes 
(Kindermann). It is possible that if the subjects were allowed to continue until the point 
of fatigue an effect on performance might have been demonstrated. However, 
Kindermann makes the point that if the group who ingested calcium antagonists tended 
to fatigue earlier than when ingesting placebo then one would have seen differences in 
the ratings of perceived exertion and this was not the case. 
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Selvey et al (1994) determined the effects of the calcium channel antagonist isradipine, 
2.5 mg twice daily for four weeks, on maximal and prolonged submaximal exercise 
performance. They found that submaximal cycling time at 75% of V02max was 
significantly reduced after the ingestion of isradipine. The rating of perceived exertion 
was also increased after isradipine ingestion during submaximal exercise. This occured 
despite no change in submaximal oxygen consumption, ventilation, muscle power output 
or blood concentrations of free fatty acids, lactate and glucose when comparing 
isradipine to placebo. Selvey suggested that the effects of certain antihypertensive 
medications may only become apparent during prolonged submaximal exercise testing 
(61 ). 
Further studies need to be undertaken to address the issue of calcium antagonists and the 
physiological response and performance during prolonged submaximal exercise as this is 
firstly the form of exercise that is prescribed for hypertensive patients, and secondly the 
type of exercise that they are most likely to take part in, not maximal exercise ( 16). 
Therefore there is a need to know the effects of these newer, commonly used agents, on 
this type of exercise. 
Haemodynamics : 
The effect that a calcium antagonist will have on the haemodynamic profile is 
determined to a large extent by the type of agent and whether it is an acute or chronic 
dose. 
i) Heart rate 
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Nifedipine 20 mg as a single oral dose increases the resting heart rate by up to 9 beats per 
minute and after a single dose a diltiazem 90 mg it is reduced by four beats per minute. 
With long term treatment these changes are attenuated (36). There are studies ~hich 
demonstrate no significant change in resting heart rate. Derman et al ( 1992 ), found 
resting heart rate to be unchanged after a single dose of nifedipine 20 mg ( 17). Studies 
looking at the chronic effects of felodipine and amlodipine failed to show any differences 
in resting heart rate (42, 43). 
Maximal heart rate as determined during incremental graded exercise appears to be 
unchanged after nifedipine ingestion (17, 26, 36, 58). However, studies using diltiazem 
and verapamil demonstrate a fall in the maximum heart rate (36, 58, 71). Luurila et al 
( 1987) demonstrated no change in maximal heart rate on diltiazem ( 44 ). 
Heart rate during submaximal exercise is significantly increased on nifedipine when 
compared to placebo (26, 36, 58). There are also studies suggesting that there is no 
change in subma~imal heart rate after the ingestion of nifedipine 20 mg ( 17). Trials using 
diltiazem and verapamil have demonstrated a decrease in the submaximal heart rate with 
both acute and long term administration ( 36, 44 ). The long acting dihydropyridines, 
felodipine and amlodipine, do not appear to affect submaximal exercise heart rate ( 42, 
43, 54). 
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The heart rate response at rest and during exercise is predi~table considering the 
mechanisms of action of the different groups of calcium channel antagonists. Nifedipine, 
having a predominantly vasodilatory effect, results in an increased sympathetic drive. 
This can be seen in the significant rise in noradrenaline after nifedipine ingestion ( 49, 
58). However, after long term administration there appears to be an attenuation in the 
response of noradrenaline to the peripheral vasodilatation. Verapamil and diltiazem 
lower blood pressure by a combination of a reduction in cardiac output and a decrease in 
the total peripheral resistance. This is accomplished by the dual action on arteriolar 
smooth muscle and the sinoatrial node. The compensatory tachycardia, seen with the 
vasodilatation, is inhibited by the inhibition on the sinoatrial node by these drugs. It 
should be noted that with the newer dihydropyridines, such as amlodipine, one does not 
see a change in heart rate at rest or during exercise when compared to placebo (42). This 
is possible as a result of the slower onset of action, negligible effect on the sino atrial 
node and longer plasma half-life, thereby ensuring a gradual vasodilation which may 
inhibit the rise in noradrenaline seen with a drug such as nifedipine. 
ii) Blood pressure, Cardiac output and Total peripheral resistance: 
There is little doubt concerning the efficacy of the calcium antagonists in lowering 
resting blood pressure (42, 43, 53, 54). Of more interest however, is the question as to 
how effective they are in lowering blood pressure in hypertensive individuals during 
maximal and submaximal exercise. It is fairly well established that the greater the pre 
treatment blood pressure is, the greater will be the antihypertensive effect with calcium 
influx inhibition (31 ). 
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In light of the above it is therefore not surprising to see that some of the studies done on 
normotensive subjects failed to show a significant reduction in blood pressure during 
either maximal or sub maximal exercise (17, 58). The total peripheral resistance is 
reduced to varying degrees with all calcium antagonists in hypertensive subjects at rest 
and during exercise. This occurs with very little change in cardiac output. However, in 
normotensive subjects the total peripheral resistance is changed very little and the effect 
on blood pressure is, therefore, relatively small (36). 
Lund Johansen (1984) determined the effects ofverapamil 120-240 mg daily in essential 
hypertensives during exercise. He found the reduction in systolic blood pressure to be 
significant ·at rest and low workloads but not significantly reduced at the higher 
workloads. The mean arterial pressure, however, was significantly reduced in all cases. 
The heart rate was reduced at rest and during exercise whilst the stroke index was 
increased thereby maintaining the cardiac output ( 41 ). Yamakado et al ( 1983) found 
diltiazem 180 mg daily sufficient to lower blood pressure in hypertensive patients during 
submaximal and maximal exercise. The heart rate was also reduced (71). Unpublished 
data from the same author suggests that cardiac output is unchanged with more strenuous 
work, thereby implying, as for verapamil, that the stroke index must have increased. 
However, there is also work suggesting that blood pressure is unaltered by diltiazem. 
Luurita et al ( 1987) compared the effects of diltiazem, mean dose 216 mg/day, and 
atenolol, mean dose 80 mg/day, versus placebo in hypertensive subjects. Whilst atenolol 
demonstrated significant reductions in blood pressure during maximal and submaximal 
exercise diltiazem was ineffective in lowering blood pressure during exercise ( 44 ). 
Lund Johansen ( 1990) studied the effects of the phenylalkylamine1 tiapamil, and the 
dihydropyridine calcium antagonists, amlodipine and felodipine, in essential 
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hypertensives during rest and exercise. He found all three drugs were successful in 
lowering blood pressure during submaximal exercise. However, the lowering of blood 
pressure after felodipine and amlodipine was entirely due to a reduction in total 
peripheral resistance whilst cardiac output was maintained. Tiaparnil did not cause a 
significant drop in the total peripheral resistance and the mechanism whereby it produced 
a reduction in blood pressure was due to a combination of a reduction in total peripheral 
resistance as well as a reduction in cardiac output due to a decrease in heart rate (43). 
The primary pathophysiological feature of essential hypertension is an increase in the 
total peripheral resistance. In the early stages of hypertension there is a slightly elevated 
cardiac output but ultimately, with left ventricular hypertrophy and a decrease in left 
ventricular ·compliance, cardiac output is reduced. This relative reduction in cardiac 
output is accentuated by exercise when compared to normotensive controls ( 40). When 
prescribing an antihypertenisive agent it would be preferable to correct the 
pathophysiology i.e. reduce the total peripheral resistance whilst at least maintaining or 
increasing the relative cardiac output. In Omvik and Lund Johansen's review ( 1993) of 
the haemodynarnics after long term antihypertensive treatment the only drugs that 
demonstrated such a favourable haemodynamic profile at rest and during exercise were 
the dihydropyridine calcium antagonists, amlodipine and felodipine, and the alpha one 
receptor blocker, doxazosin (54 ). 
Metabolic response : 
Many of the hormones produced by the endocrine pancreas, anterior pituitary and adrenal 
medulla have a calcium dependent mechanism of release (36). Therefore it is possible 
that the calcium antagonists could affect the release of these hormones and thereby alter 
the metabolic response to exercise. Raff es tin et al ( 1985) demonstrated significantly 
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higher concentrations of growth hormone during submaximal exercise. This was thought 
to be due to the increased sympathetic drive as demonstrated by the significantly higher 
concentrations of noradrenaline. It should be emphasised that this was an acute dose 
study where the catecholamine response is known to be greater. However to date, many 
of the trials undertaken during exercise, after long term treatment, have not demonstrated 
a change in serum insulin, growth hormone or cortisol (36, 58). 
i) Catecholamines: 
Nifedipine invokes an increase in plasma noradrenaline concentration both at rest and 
during exercise, but plasma adrenaline concentrations are unaffected (15, 39, 49, 58, 60). 
After long term administration, however, the rise in plasma noradrenaline concentration 
is attenuated. Plasma adrenaline and noradrenaline concentrations are unaffected by 
diltiazem or verapimil both at rest and during exercise, when compared to placebo (14, 
49, 60 ). It is likely that the greater vasodilatory effect of nifedipine results in a reflex 
activation of the sympathetic nervous system, particularly after acute dosing, whereas this 
is not seen with verapamil or diltiazem which have predominant cardiac effects. An 
increased plasma renin concentration was found in subjects at rest after nifedipine 
ingestion which woul_d correlate with an increased sympathetic activity (39). However, 
after long term administration of nifedipine one sees far less of a change in noradrenaline 
and renin activity. It would appear that the long term administration of nifedipine 
attenuates the compensatory mechanisms that occur after acute ingestion (36). There 
appears to be no effect of diltiazem or verapamil on serum noradrenaline or renin activity 
during steady state exercise. 
ii) Carbohydrate metabolism : 
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During both steady state and maximal exercise there are no significant differences in 
blood lactate or glucose concentrations after long tenn administration of nifedipine and 
verapamil (36, 57). Raffestin et al ( 1985) demonstrated significantly higher blood 
glucose and lactate concentrations after nifedipine compared to placebo during 
submaximal exercise. He reasoned that this was due to the increased sympathetic drive 
which would account for an increased gluconeogenic and glycolytic flux and hence 
explain the higher lactate and glucose concentrations. However, Kindennann (1987) 
reported higher blood lactate concentrations after diltiazem and nifedipine when 
compared to placebo during prolonged submaximal exercise. The blood lactate 
concentration was slightly higher after diltiazem than after nifedipine, but not 
significantly so. Neither were the blood lactate concentrations significantly different to 
placebo. Kindennann makes the point that diltiazem brought about no reflex increase in 
sympathetic activity and therefore the greater concentrations of blood glucose and lactate 
demonstrated in Raffestin's trial cannot be explained by an increase in beta adrenergic 
stimulation of glycolysis and gluconeogenesis. However two points need to be 
highlighted in order to clarify these contradictory findings. Firstly, in Kindennann's study 
the actual differences in the lactate concentrations after calcium antagonist and placebo 
ingestion were very small (0.2 mmol/L after nifedipine and 0.7 mmol/L after diltiazem). 
In Raffestin's study there were much greater and significant differences in lactate 
concentration after nifedipine compared to placebo (58). It is possible that Kindennann's 
findings were simply due to random variation and there was no real difference in his 
results. Secondly, Raffestin used an acute dose in his trial which would induce a greater 
catecholamine response than long term administration, such as in Kindermann ( 1987) 
and Petri's ( 1986) trial. 
In summary, it would appear that only those trials using acute doses of nifedipine 
demonstrated any real difference in carbohydrate metabolism and it is likely to be 
explained by the greater catecholamine response induced by this agent. 
iii) Lipid Metabolism : 
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Free fatty acid and glycerol levels during exercise are unaffected by the long term 
administration of nifedipine or diltiazem. The respiratory exchange ratio is also unaltered 
when compared with placebo (36). Again it is Raffestin, using an acute dose of 
nifedipine, who demonsrated a difference in free fatty acids during the recovery phase 
after steady state exercise. It is possible that this may also be explained by increased 
lipolysis during exercise due to the increase in circulating noradrenaline. This would 
correlate well with the fall in the respiratory exchange ratio (RER) values which 
Raffestin found towards the end of the steady state exercise when on nifedipine (58). 
Summary: 
Much of the data reviewed thus far would suggest that neither submaximal or maximal 
exercise performance is adversely affected by the calcium channel antagonists after long 
term administration. In those studies that do reveal a reduction in performance, it is 
minimal. -Cardiac pump function is maintained during exercise. There is, however, some 
doubt as to whether the calcium antagonists are effective in lowering blood pressure 
during exercise. In Omvik's review ( 1993) he suggests that the vast majority of drugs 
except epanolol were unsuccessful in decreasing the relative rise in blood pressure during 
exercise, but perhaps it is not the relative but the absolute rise that needs to be reduced 
for the acute and chronic end organ protection. 
- -------~-~-----.... 
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The honnonal and metabolic responses to exercise when a calcium antagoni
sts is used in 
the long tennis unchanged. This is not the case when Beta blockers are used
 (70). 
Therefore the calcium antagonists are attractive options when chosing a drug
 for the 
athletic or physically active hypertensive. The new dihydropyridine, amlodip
ine, is a 
once daily dose, long acting antihypertensive. It is effective in ensuring 24 hour bloo
d 
pressure control with very few side effects (30). The type of exercise prescrib
ed for 
hypertensive patients is of the prolonged submaximal type, however there is 
a paucity of 
data on perfonnance and the physiological response to such exercise. Theref
ore the aim 
of this study is to detennine the physiological response to maximal and prolo
nged steady 
state exercise after amlodipine ingestion. 
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THE EFFECTS OF AMLODIPINE ON EXERCISE PERFORMANCE 
IN MILD TO MODERATE ESSENTIAL HYPERTENSIVES 
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INTRODUCTION 
It is well documented that regular aerobic exercise is beneficial in the prevention and 
treatment of hypertension (1, 2, 4, 5, 6, 10, 16, 20, 25, 29, 47, 50, 59, 63 , 64). Therefore 
physical exercise is an important component in the comprehensive management of 
patients with hypertension. The fifth report of the joint national committee on detection, 
evaluation and treatment of high blood pressure (JNC V), suggests that exercise 
performed daily at an intensity of 40% to 60% of an individual's maximum oxygen · 
consumption effectively lowers blood pressure in hypertensive subjects (50, 63). Since an 
increasing number of hypertensive patients will become involved in exercise 
programmes, it is essential that the medications used to treat hypertension do not 
interfere with the patients capacity to perform prolonged submaximal exercise. 
Many of the traditionally prescribed antihypertensives, particularly the beta-blockers, 
impair exercise tolerance (55, 62, 65, 68). The calcium antagonists would appear to be 
one of the preferred agents for use in physically active patients (17, 36, 42, 43, 58). 
However, available data suggest that these agents are not devoid of an effect on exercise 
performance (17, 27, 61 ). Most research has concentrated on the effects of calcium 
antagonists on maximal exercise performance and very few involve the newer, long 
acting, dihydropyridine calcium channel antagonists. Furthermore, prolonged 
submaximal exercise is the optimum exercise mode for patients with hypertension. 
Hence, there is the need to establish whether the dihydropyridine calcium channel 
antagonists impair prolonged exercise performance. 
Previous studies suggest that the dihydropyridine calcium antagonists effectively lower 
total peripheral resistance while maintain cardiac output at rest and during seven to eight 
minutes of submaximal exercise ( 42, 43 ). However, there are few data on cardiac output 
and performance during more prolonged exercise, which is the type of exercise 
hypertensive patients take part in. Furthermore, the physiological response to maximal 
and submaximal exercise after the ingestion of amlodipine, a new dihydropyridine 
calcium channel antagonist, is unknown. 
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Therefore the aim of this study is to determine the effects of amiodipine on the 
physiological response to, and performance during, maximal and prolonged submaximal 
exercise. In order to determine if amlodipine influences the contractile properties of 
skeletal muscle, muscle function testing was also performed prior to and immediately 
after submaximal exercise. 
~IA TERIALS AND METHODS 
Medication and Study Design: 
The effects of 5mg amlodipine ingested once daily on physiological measures ~nd 
performance during maximal and prolonged submaximal exercise were compared in a 
double blind, randomised, crossover study. A two week placebo run in period was 
employed. This was followed by two, two week treatment periods seperated by a fourteen 
day washout period ( fig. l ). 
Subjects and testing methods : 
The study was approved by the American Food and Drug Administration and the Ethics 
and Research Committee of the Faculty of Medicine at the University of Cape Town. All 
subjects provided written informed consent and were given a full medical examination 
and resting electrocardiogram prior to the start of the study. Subjects for the study were 
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10 male, hypertensive, recreational athletes. To be included in the study mean supine 
diastolic blood pressure had to be between 95 and 115 mmHg, determined as the mean of 
three recordings at the end of the placebo run in period; and the subjects had to be free of 
any other cardiovascular, respiratory, or musculoskeletal disorders. 
Subjects were asked to maintain their usual training programme throughout the trial in 
order that a constant level of fitness be maintained. Strenuous physical exercise was to be 
avoided for the 24 hours preceeding each laboratory test. No caffeine containing foods or 
drinks were to be consumed on the day of testing. All tests were performed at the same 
time of day, approximately three hours after the ingestion of the last dose of medicatio!'l. 
Subjects reported to the laboratory at the end of the placebo run 1n period (end of week 
2), to perform a familiarization maximal cycle test (fig 1). The maximum oxygen 
consumption (V02max) measured in this test was used to determine ·the workload used 
in the prolonged submaximal exercise test. 
Test 1 Test 2 Test 3 
Placebo BP Drug 1 Max Oav1 I WASHOUT I Drug 2 Max Dav 1 
run in Max 
.. 
Submax Submax 
Familiarisation Oay2 Dav 2 
Week1 Week2 Week3 Week4 Week 5&8 Week7 Weeki 
Fig I. Trial protocol. Abbreviations: BP, blood pressure. Max. incremental graded test to exhaustion. 
Submax. prolonged subrnaximal test at 75% of maximum oxygen consumption. 
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Systolic and diastolic blood pressure and heart rate were .measured whilst supine and 
after 5 minutes of standing (average of three readings, one minute apart), at the end of
 
each week. All blood pressure readings were taken by the same investigator throughou
t 
the trial using a mercury sphygmomanometer (Standby, W.A. Baum Co. Inc; New Yor
k, 
USA) recording Korotkoff phase I and N . 
Subjects then ingested either placebo or amlodipine for two weeks followed by a two 
week washout period, whereafter they ingested either amlodipine or placebo ( cross ov
er) 
for a further two weeks. At the end of weeks 4 and 8, subjects performed a maximum 
cycle test to exhaustion for determination of V02max and blood pressure measuremen
ts. 
Heart rate, rating of perceived exertion and blood lactate concentrations were also 
measured. The following day subjects performed a prolonged submaximal test at 75%
 
V02max for determination of cardiac output, time to fatigue; heart rate, blood pressure
, 
and blood concentrations of lactate, glucose and free fatty acids. 
Incremental Graded exercise testing to exhaustion: 
For measurement of V02max and physiological changes during maximal exercise, 
subjects performed maximal progressive exercise to exhaustion on an electro-
mechanically braked cycle ergometer (Siemens, Johannesburg, South Africa). 
A self paced warm up was allowed. Subjects started pedalling at a workload of700 
kiloponds. The workload was increased by 100 kiloponds every minute until the subje
ct 
voluntarily terminated the test. 
Blood was sampled every minute through an indwelling intravenous catheter (Jelco 
Teflon, Halfway House, South Africa) for determination of plasma lactate concentrati
on 
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(Lactate Pap, Bio Merieux, Lyon, France). Blood samples were centrifuged, seperated 
and then frozen for later analysis. Blood pressure was measured every minute by means 
of audible sphygmomanometry using a calibrated mercury column sphygmomanometer, 
with the appropriate sized cuff, as previously detailed (Standby, W.A. Baum Co. Inc, 
New York, USA). Korotkoff phase f & IV were used. Heart rate was determined each 
minute using an electrocardiogram monitor (Lohmerier, Munich, Germany) with self 
adhering electrodes in the CM 5 position. 
During exercise inspired and expired air was analysed for oxygen and carbon dioxide 
content as well as inspiratory volume using the Cardiopulmonary Exercise System 
(Medical Graphics Corporation, CPX / D Series 2 Model No 762018-101, St Paul, 
Minnesotta, USA). Both analysers were calibrated before each test using gases of known 
composition. 
The V02max was taken as the highest rate of oxygen consumption measured during any 
60 second period (Noakes et al 1988). Rates of oxygen consumption (V02), carbon 
dioxide production (VC02), respiratory exchange ratio (RER) and ventilation (Vi) were 
recorded for every breath cycle. Every 30 seconds the average value of the preceding 9 
breaths was recorded and stored for later printing. 
Peak workload was taken as the highest workload (kiloponds) maintained for a complete 
minute during the test. When a subject was unable to complete the full minute at a 
particular workload, the workload of the immediately preceding, completed workload 
was recorded as the peak workload. Exercise time to exhaustion was taken to the nearest 
30 seconds. 
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Subjects were asked to report their level of perceived exertion from the appropriate scale 
during each minute of the exercise test (Borg 1982). 
Prolonged submaximal exercise testing: 
Prolonged submaximal exercise testing was performed the day following the incremental 
maximum test. Subjects cycled at a workload corresponding to 75% of their 
predetermined V02max· They were to maintain a cadence between 60 and 70 rpm for 
one hour or until they could no longer maintain a cadence in excess of 60 rpm. 
Blood was sampled through an intravenous catheter at rest, 20 min, 40 min, 60 min and 
10 minutes after the termination of exercise. Plama lactate concentrations were 
determined as previously described. Plasma glucose concentrations were determined 
using the Beckman Glucose analyser 2 (Brea, California, USA). Serum free fatty acid 
concyntrations were determined with a standard enzymatic kit method (Free Fatty Acids, 
Half-Micro test, Boehringer Mannheim Biochemica, Germany). 
Blood pressure, heart rate and rating of perceived exertion were recorded every 15 
minutes as previously described. 
The rate of oxygen consumption (V02), carbon dioxide production (VC02), respiratory 
exchange ratio (RER) and ventilation (Vi) were recorded every 15 minutes using the 
same cardiopulmonary exercise system (Medical Graphics Corporation, CPX / D Series 
2, Model No 762018-101, St Paul, Minnesotta, USA). 
Determination of cardiac output was based on the Fick principle. Cardiac output was 
measured every 15 minutes using the indirect, Defares rebreathing method (32). All of 
•. : JD 
the calculations required were perfonned by the computerised cardiopulmonary exercise system. 
The total peripheral resistance was calculated by dividing the cardiac output by the mean arterial pressure (MAP). MAP was calculated by adding 1/3 of the pulse pressure to the diastolic blood pressure (3). 
Tests of skeletal muscle function: 
Tests of skeletal muscle function were perfonned prior to and directly after the submaximal exercise test. The maximal voluntary isometric torque produced by the right quadriceps muscle was measured on a custom made, leg stabilising chair according to methods previously described (12). Each subject first performed 4-5 maximum voluntary contractions (MVC). After a recovery period, subjects perfonned repetitive maximum voluntary isometric contractions for 6 ~econds followed by a 4 second rest period. Maximum contractions were repeated until the subject was unable to maintain a torque greater than or equal to 70% of the initial MVC for at least 3 seconds of the 6 second contraction. The duration of activity to this point was recorded as the time to fatigue. The value is considered to be a measure of the resistance of the skeletal muscle to fatigue (Coetzer et al 1993). 
Statistical analysis 
The significance of differences between the variables over time and between trials when on amlodipine or placebo were analysed using a one way analysis of variance. The Student's t - test using two tailed p values corrected for unequal variances was used when · comparing the mean values of data at the various time intervals. Significance was 
-.··.··· 
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established at the 0.05 confidence level. All data are presented as the means± standard 
deviations of the mean. When comparing sample means of groups with n < 10, Levene's 
test for homogeneity was used. If the variances were found to be unequal then the Mann 
Whitney U test for unpaired data was applied. 
RESULTS 
Subject characteristics 
Subjects for the study were 10 male recreational athletes of mean age 45 ± 8 yrs (range 
28 - 53 yrs), mean height 176 ± 9 cm (range 156 - 189 cm), mean mass 80 ± 10 kg (range 
65 -96 kg)~ and mean V02max 34 ± 7 ml.02.kg-l .min-l (range 24-43 ml.02.kg-l .min-
l ). 
Resting cardiovascular measurements 
The mean standing systolic blood pressure at rest after the two week placebo run in 
period was 147 ± 18 mm Hg whilst the mean diastolic blood pressure was 103 ± 6 mm 
Hg. Systolic pressure after two weeks of placebo was 142 ± 13 mm Hg and diastolic 
pressure was 100 ± 9 mm Hg. Systolic blood pressure decreased to 133 ± 12 mm Hg 
(p<0.05) and diastolic blood pressure tended to be lower at 95 ± 8 mm Hg after the 
ingestion of amlodipine (fig 2). Heart rate at rest was unchanged (74 ± 12 beats per 
minute vs 73 ± 12 beats per minute, amlodipine vs placebo) (fig 3). 






RESTING BLOOD PRESSURE 
200 
~ PLACEBO RUN IN 
175 D PLACEBO 
150 ~ AMLOOIPINE 5mg 
125 
SYSTOLIC DIASTOLIC 
Fig 2. Resting blood pressw-e measw-ernents in the standing 
position. • = P<0.05 \ 'S placeho \·alues. All va lu,:s an: means 
±SD. 
Resting heart rate ( beats.min-I 
Peak heart rate ( beats.min-I ) 
Resting systolic blood pressure (mmHg) 
Peak systolic blood pressure (mmHg) 
vo2 max ( ml.02_kg-l .min-l) 
Peak RER 
Ventilation (Litres.min- I 
Time to fatigue (minutes ) 
Maximum workload (kpm.mi1f 1) 








73 ± 12 
165 ± 16 
142 ± 13 
170 ± 16 
33 .1 ± 4.9 
1.17 ± 0.01 
110.4 ± 20.9 
8.J ± 1.7 
143 5 ± 176 
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~ [N PLACEBO AMLODIPINE 
Fig. 3. Resting heart rate in the standing position. 
AMLODIPINE 
74 ± 12 
168 ± l3 
133 ± 12 
181 ± 21 
30.5 ± 4.8 
1.26 ± 0.1 
106.2 ± 22.2 
8. 15 ± l.8 
1415 ± 179 
Table 3 : Physiological measurements at rest and during maximal exercise. Data are presented as means 
and standard deviations. Abbreviations ( V02 max ) maximum o:-..·ygen consumption. RER, respiratory 
exchange ratio. 
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Data from the maximum tests at peak exercise are documented in Table 3. Although the 
mean V02max, time to fatigue and maximum work load tended to be lower with 
amlodipine, the differences were not significant. Heart rate and ventilation were 
unaffected by amlodipine. Peak systolic blood pressure tended to be higher after 
amlodipine. 
Measurements of systolic blood pressure, heart rate, plasma lactate concentration, oxygen 
consumption (V02), ventilation (Vi) and respiratory exchange ratio were not different 
during exercise with either amlodipine or placebo. The rating of perceived exertion was 
higher after the fifth minute of exercise following amlodipine ingestion whereas blood 
lactate concentrations were not different ( figs 4-10). 
Exercise performance and cardiorespiratory measurements during submaximal. 
exercise: 
Mean time to fatigue was 41 ± 19 min after the ingestion of amlodipine compared with 
44 ± 19 min after placebo ( fig 11 ). Ratings of perceived exertion, minute ventilation and 
submaximal V02 were not statistically different between the trials. However, 
submaximal (V02) tended to be lower following amlodipine ingestion (figs 12-14 ). 
Haemodynamic measurements: 
Heart rate, cardiac output, systolic blood pressure and total peripheral resistance were not 
different after amlodipine ingestion compared to placebo (figs 15-18). 
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fig 5. Heart rate during 11ax. test. Paired data ar. shown 
up to oinute 8 whereatter > 50X of the · sutljects had 
terwinated esercise. 
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> SOX of the subjects hed terninated exercise. 






o PLACEBO lJ 
o....____., _ _.__.__-'-_.,____._....L,._"-....J 
fig 9. Paired data are shown up to llin 8 -utter 
> 50X af the s<.t,jects had terainated enn::iu. 
0 1 2 3 4 5 6 7 8 9 
TIME (MIN) 
fig 10. ~atJng of percetved exertion ct.Jr,ng ,..,._ test. Paired 
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Fig 12. Rating of perce1Yed exertion using the 11odified • 
Borg scale. Only paired data are shol,n. At 15 llin n•IO, 
30 •in na 7, 45 ain naS. 60 11in n•J. 
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Fig 15. Only paired data are sho .. n. At 15 min n•lO, 
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Fig 17. Only paired data are shown. At 15 min nalO, 
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Fig 16. Only paiired data are shown. At min 15 n=IO, 
30 min n=7, 45 min n=5, 60 min n=3. 
SYSTOLIC BLOOD PRESSURE 
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Fig 18. Only paared data an, shown. At IS min n=IO, 
30 min n=7. 45 min n=5. 60 min n=3. 
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.Skeletal muscle function: 
Muscle function was not different between trials when comparing values prior to and 
after exercise (fig19). Mean maximum voluntary contraction prior to and post exercise 
was not different when comparing amlodipine with placebo. The time to fatigue prior to 
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Fig 20. Plasma glucose concentrations at rest 20. 40, 60 
and 10 n.n post ternin..t ion of exercise. Only paired data are 
shown. At 20 nin n=lO, 40 nin n=7, 60 nin n=3. 
Fig 21. Plasma lactate concentration at rest. 20, 40, 60 and 
10 min post termination of exercise. Only paired data 
are shown. At 20 11in n-10, 40 •in n•7. 60 llin ,.,.J. 
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Fig 22. Pln•a free fatty acid concentration at rest 20. 40, 
60 and 10 m,n post tern.nation of exercise. Only paired 
data are shown. At 20 min n=lO. ~O 11in n=7. 60 min n=J. 
Plasma glucose, lactate and free fatty acid concentrations: 
Plasma glucose, lactate and free fatty acid concentrations were not different between 
trials (figs 20-22). 
Discussion 
Essential hypertension is an extremely common disorder. The widespread availability of 
large numbers of athletic hypertensive patients, willing to undergo invasive exercise 
testing, is not common. As a result incorporating large numbers of subjects into·such 
studies is difficult. Therefore studies such as the current one, with small numbers of 
subjects, are prone to type II error. Therefore the power to detect significant differences 
is greatly reduced. However, accepting this proviso, the current study does demonstrates 
a number of important findings. First, 5 mg of amlodipine ingested once daily over a two 
week period, effectively lowered systolic blood pressure at rest in physically active, 
hypertensive individuals. Resting heart rate was unaffected by ingestion of amlodipine. 
This is in agreement with other studies (42, 54). 
Second, maximal exercise performance measured as peak achieved work load was 
unaffected by the ingestion of amlodipine. This would concur with the findings of other 
studies after the long term administration of calcium antagonists (36, 44, 57, 71). There 
are studies which demonstrate a reduction in performance after the acute ingestion of 
nifedipine; the aetiology of this effect is not immediately apparent (17, 26). However, 
there is evidence to suggest that the physiological response after the acute ingestion of 
antihypertensive agents is different to the physiological response after the long term 
administration (53, 54 ). Therefore, it is possible that the altered physiology may explain 
the reduction in performance. 
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To date, as far as we are aware, there is only one study demonstrating a reduction in 
prolonged submaximal exercise performance in hypertensive subjects after the ingestion 
of a dihydropyridine. Selvey et al ( 1994) demonstrated a significant reduction in 
prolonged submaximal exercise performance as well as higher ratings of perceived 
exertion after the ingestion of isradipine. They concluded that the reduction in 
performance after the ingestion of isradipine occurred despite unchanged cardiovascular · 
and physiological measurements, as well as no change in measurements of muscle power 
when compared to placebo. Therefore, the reason for the decrease in performance was 
not immediately apparent. Selvey et al suggested that the effects of certain 
antihypertensives may only become apparent during prolonged submaximal exercise 
(61 ). 
However, the third important finding in the present study was that prolonged submaximal 
exercise · performance was not affected by the ingestion of amlodipine in keeping with 
previous studies (36, 58). A criticism of these studies is that the exercise was not 
continued until volitional exhaustion but was discontinued after pre-set times of 45 
minutes (58) and 50 minutes (36). All subjects in these studies completed the required 
exercise time. In the latter it was argued that if there was to be a difference in 
performance beyond 50 minutes then this would have been reflected in the preceding 
ratings of perceived exertion when compared to placebo, however these were not 
different. 
The fourth finding of the study was that systolic blood pressure and heart rate were not 
altered during incremental graded exercise after the ingestion of amlodipine when 
compared to placebo. The effects on heart rate are in keeping with the findings of Lund 
Johansen et al ( 42, 43). However, they found that submaximal systolic blood pressure 
was significantly lower at all work loads, predominantly due to a fall in total peripheral 
resistance, after the ingestion of amlodipine. 
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Cardiac output, systolic blood pressure, heart rate and total peripheral resistance were not 
affected during prolonged submaximal exercise after the ingestion of amlodipine in the 
present study. As previously indicated, these findings contrast with those of Lund 
Johansen et al ( 1990) who found that systolic blood pressure was significantly decreased 
at submaximal work loads after the long term ingestion of amlodipine ( 42) and felodipine 
( 43 ). Cardiac output was either unchanged ( felodipine) or increased ( amlodipine ). The 
reduction in blood pressure was entirely due to a decrease in the total peripheral 
resistance. Therefore, it is surprising that no difference in blood pressure was detected 
during exeraise after the ingestion of amlodipine in the current study. 
The lack of a measurable change in exercising blood pressure in our subjects might be 
explained by a number of possibilities or a combination thereof. Firstly, amlodipine may 
have had no effect on exercising blood pressure due to the subjects' physically trained 
state. Secondly, the exercising blood pressure may have been reduced but the actual 
reduction might have been too small to be detected due to an inadequate washout period, 
inherent difficulties with indirect blood pressure measurement or the dosage of 
amlodipine used. These points will be discussed in detail below. 
\ 
i) The subjects in the current study were a hypertensive population with a mean systolic 
blood pressure after the placebo run in of 147 ± 18 mm Hg and diastolic blood pressure 
of l 03 ± 6 mm Hg. However, the systolic blood pressure of these subjects, during both 
prolonged submaximal and maximal exercise, ;Vas not characteristic of a true 
hypertensive response to exercise. The American College of Sports Medicine describe a 
hypertensive response to exercise as one in which the peak exercising systolic blood 
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pressure is greater than 225 mm Hg (2). However, the subjects in the present study had a 
mean peak systolic blood pressure of 170 ± 16 mm Hg during the incremental maximum 
test after placebo ingestion. In both of Lund Johansen et al's trials (42, 43) the subjects 
had a mean systolic blood pressure of> 200 mm Hg at 100 watts of submaximal exercise 
after the ingestion of placebo. A work load of l 00 Watts corresponds to approximately 
700 kiloponds which is equivalent to the work load at which our subjects began cycling 
during the maximum test. Mean systolic blood pressure at this work load after the 
ingestion of placebo was 137 ± 14 mm Hg. Therefore, although the subjects in the 
present study are truly hypertensive as reflected by their resting blood pressure 
measurements whilst on placebo, the increase in blood pressure during exercise is not of 
the magnitude one would expect with untrained hypertensive subjects. It is known that 
the higher the blood pressure, the greater the effect of calcium channel antagonists in 
reducing it (31 ). It is therefore possible that, due to their state of physical training 
resulting in a lower exercising blood pressure response compared to untrained 
hypertensive subjects, calcium antagonists might not have had as great an effect on 
systolic blood pressure during exercise. 
The second possibility was that there may have been a reduction in blood pressure but 
this was too small to be detected. 
ii) The washout period period used in the current study was ten days. Amlodopine is 
recomended as a once daily dosage due to the long plasma half-life. It is therefore 
possible that the two week washout period may not have been adequate for subjects to 
clear the drug effectively. Therefore, the subjects who ingested placebo second may not 
have been completely clear of amlodopine. As a result, exercising blood pressure 
measured during that part of the trial may have been reduced due to the residual effects 
of amlodipine and thereby resulting in a falsely reduced mean exercising systolic blood 
pressure in the placebo group. 
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iii) The percent change in systolic blood pressure at rest was only 6% after the ingestion 
of amlodipine. Using intra-arterial blood pressure monitoring, it has been shown that the 
percent reduction in systolic blood pressure at rest is greater than the percent reduction 
during exercise after long term administration of calcium channel antagonists ( 54 ). It is 
therefore possible that, due to the difficulty in accurately measuring blood pressure 
during exercise using the indirect technique, we may not have been able to detect small 
( < 6%) changes in systolic blood pressure during submaximal exercise (21 , 28, 69). 
iv) Finally, ·in Lund Johansen's trials higher mean doses of dihydropyridines were used, 9 
mg of amlodipine and 15 mg of felodipine daily compared to the 5 mg of amlodipine 
used in our study ( 42, 43 ). Therefore 5 mg of amlodipine may not have been sufficient to 
significantly lower exercising blood pressure in our subjects. 
During the incremental graded exercise test the rating of perceived exertion (RPE) 
tended to be higher beyond the fifth minute after the ingestion of amlodipine, and at 
minute seven it was significantly higher. However the other physiological variables such 
as oxygen consumption (V02), respiratory exchange ratio (RER), plasma lactate 
concentration and minute ventilation were not different during prolonged submaximal 
exercise following the ingestion of amlodipine. Derman et al ( 1992) also found a higher 
RPE after the ingestion of calcium antagonists and they speculated that it might be due to 
an effect on the central nervous system or impaired muscle contractile function ( 17). 
Muscle function testing before and after the prolonged submaximal test, revealed no 
differences between drug and placebo in our trial thereby excluding increased skeletal 
muscle fatigue as a cause of the increased perception of effort. Furthermore there was no 
45 
change in performance suggesting that the contractile properties of skeletal muscle 
during the maximal test were maintained. Therefore the reason for the increased rating ot 
perceived exertion in the latter stages of the incremental test is not directly apparent but 
was not related to changes in oxygen consumption, respiratory exchange ratio, minute 
ventilation, plasma lactate concentrations or skeletal muscle function. 
During prolonged submaximal exercise, oxygen consumption, rating of perceived 
exertion, minute ventilation, plasma glucose and lactate concentrations and blood free 
fatty acid concentrations, were not altered by amlodipine ingestion which is in keeping 
with other studies (36). However, the potential problems with the long haif life of 
amlodipine as described earlier, may have affected these variables as well. 
Conclusion 
This study has extended previous work on the effects of ingestion of long acting calcium 
antagonists, in particular the dihydropyridines, on exercise performance. We conclude 
that the daily administration of 5 mg of amlodipine over two weeks is effective in 
lowering resting systolic pressure but the haemodynamic response during exercise, in 
athleticly trained hypertensive individuals, was not significantly different when compared 
to placebo. Maximal, prolonged submaximal exercise performance and skeletal muscle 
function are unaltered following the ingestion of amlodipine in these patients. The 
sample size in the current study is small and therefore the findings are limited by the 
possibility of a type II error. However, amlodipine would appear to be a physiologically 
appropriate and effective drug for the use in physically active hypertensive patients. 
Further studies with greater subject numbers are needed. 
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